Which has better valuation and earnings, ZYME or CGON?

Zymeworks has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zymeworks $105.96M 16.04 -$81.13M -$2.02 N/A CG Oncology $4.04M 1,660.49 -$160.99M -$2.69 N/A

Is ZYME or CGON more profitable?

Zymeworks has a net margin of -405.31% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -26.58% beat Zymeworks' return on equity. Company Net Margins Return on Equity Return on Assets Zymeworks -405.31% -72.30% -37.18% CG Oncology -3,602.68% -26.58% -25.34%

Does the media refer more to ZYME or CGON?

In the previous week, CG Oncology had 13 more articles in the media than Zymeworks. MarketBeat recorded 29 mentions for CG Oncology and 16 mentions for Zymeworks. CG Oncology's average media sentiment score of 0.03 beat Zymeworks' score of -0.01 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral CG Oncology 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Is PTCT or ZYME more profitable?

PTC Therapeutics has a net margin of -3.80% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -3.80% -362.45% -1.32% Zymeworks -405.31% -72.30% -37.18%

Does the media prefer PTCT or ZYME?

In the previous week, Zymeworks had 7 more articles in the media than PTC Therapeutics. MarketBeat recorded 16 mentions for Zymeworks and 9 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.47 beat Zymeworks' score of -0.01 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zymeworks 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer ZYME or XENE?

In the previous week, Zymeworks had 1 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 16 mentions for Zymeworks and 15 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Zymeworks' score of -0.01 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Xenon Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ZYME or DNTH?

In the previous week, Dianthus Therapeutics had 19 more articles in the media than Zymeworks. MarketBeat recorded 35 mentions for Dianthus Therapeutics and 16 mentions for Zymeworks. Dianthus Therapeutics' average media sentiment score of 0.54 beat Zymeworks' score of -0.01 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Dianthus Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Zymeworks (ZYME) Competitors

$23.95 +0.41 (+1.75%)

As of 11:09 AM Eastern

Compare

ZYME vs. CGON, PTCT, XENE, DNTH, and KNSA

Should you buy Zymeworks stock or one of its competitors? MarketBeat compares Zymeworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Zymeworks include CG Oncology (CGON), PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), Dianthus Therapeutics (DNTH), and Kiniksa Pharmaceuticals International (KNSA). These companies are all part of the "biotechnology" industry.

How does Zymeworks compare to CG Oncology?

Zymeworks (NASDAQ:ZYME) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Zymeworks has a net margin of -405.31% compared to CG Oncology's net margin of -3,602.68%. CG Oncology's return on equity of -26.58% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
CG Oncology	-3,602.68%	-26.58%	-25.34%

Zymeworks has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.04	-$81.13M	-$2.02	N/A
CG Oncology	$4.04M	1,660.49	-$160.99M	-$2.69	N/A

Zymeworks has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.23, suggesting that its stock price is 77% less volatile than the broader market.

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Zymeworks currently has a consensus price target of $38.22, indicating a potential upside of 59.59%. CG Oncology has a consensus price target of $83.18, indicating a potential upside of 9.91%. Given Zymeworks' stronger consensus rating and higher probable upside, equities analysts clearly believe Zymeworks is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, CG Oncology had 13 more articles in the media than Zymeworks. MarketBeat recorded 29 mentions for CG Oncology and 16 mentions for Zymeworks. CG Oncology's average media sentiment score of 0.03 beat Zymeworks' score of -0.01 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
CG Oncology	7 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Zymeworks beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does Zymeworks compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Zymeworks (NASDAQ:ZYME) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

PTC Therapeutics has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Zymeworks has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

92.9% of Zymeworks shares are held by institutional investors. 5.3% of PTC Therapeutics shares are held by insiders. Comparatively, 33.5% of Zymeworks shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than Zymeworks. PTC Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.58	$682.64M	-$0.58	N/A
Zymeworks	$105.96M	16.04	-$81.13M	-$2.02	N/A

In the previous week, Zymeworks had 7 more articles in the media than PTC Therapeutics. MarketBeat recorded 16 mentions for Zymeworks and 9 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.47 beat Zymeworks' score of -0.01 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zymeworks	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

PTC Therapeutics presently has a consensus price target of $98.09, indicating a potential upside of 32.22%. Zymeworks has a consensus price target of $38.22, indicating a potential upside of 59.59%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts clearly believe Zymeworks is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

PTC Therapeutics has a net margin of -3.80% compared to Zymeworks' net margin of -405.31%. Zymeworks' return on equity of -72.30% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	-362.45%	-1.32%
Zymeworks	-405.31%	-72.30%	-37.18%

Summary

Zymeworks beats PTC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Xenon Pharmaceuticals?

Zymeworks (NASDAQ:ZYME) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Zymeworks had 1 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 16 mentions for Zymeworks and 15 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.65 beat Zymeworks' score of -0.01 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.04	-$81.13M	-$2.02	N/A
Xenon Pharmaceuticals	$7.50M	816.63	-$345.91M	-$4.74	N/A

Zymeworks presently has a consensus price target of $38.22, indicating a potential upside of 59.59%. Xenon Pharmaceuticals has a consensus price target of $77.13, indicating a potential upside of 21.74%. Given Zymeworks' higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

Xenon Pharmaceuticals has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Xenon Pharmaceuticals' return on equity of -43.98% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 33.5% of Zymeworks shares are held by insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zymeworks has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Summary

Zymeworks beats Xenon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Zymeworks compare to Dianthus Therapeutics?

Zymeworks (NASDAQ:ZYME) and Dianthus Therapeutics (NASDAQ:DNTH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations, media sentiment and institutional ownership.

Zymeworks has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Dianthus Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

In the previous week, Dianthus Therapeutics had 19 more articles in the media than Zymeworks. MarketBeat recorded 35 mentions for Dianthus Therapeutics and 16 mentions for Zymeworks. Dianthus Therapeutics' average media sentiment score of 0.54 beat Zymeworks' score of -0.01 indicating that Dianthus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Dianthus Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 3.0% of Dianthus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zymeworks currently has a consensus target price of $38.22, suggesting a potential upside of 59.59%. Dianthus Therapeutics has a consensus target price of $124.27, suggesting a potential upside of 13.26%. Given Zymeworks' higher probable upside, equities analysts clearly believe Zymeworks is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

Zymeworks has a net margin of -405.31% compared to Dianthus Therapeutics' net margin of -10,096.95%. Dianthus Therapeutics' return on equity of -22.53% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%

Zymeworks has higher revenue and earnings than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.04	-$81.13M	-$2.02	N/A
Dianthus Therapeutics	$2.04M	2,940.52	-$162.34M	-$4.15	N/A

Summary

Zymeworks and Dianthus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Zymeworks compare to Kiniksa Pharmaceuticals International?

Zymeworks (NASDAQ:ZYME) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.04	-$81.13M	-$2.02	N/A
Kiniksa Pharmaceuticals International	$677.56M	8.86	$59.01M	$0.97	79.34

Zymeworks has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Zymeworks had 9 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 16 mentions for Zymeworks and 7 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 1.36 beat Zymeworks' score of -0.01 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zymeworks currently has a consensus target price of $38.22, suggesting a potential upside of 59.59%. Kiniksa Pharmaceuticals International has a consensus target price of $87.38, suggesting a potential upside of 13.54%. Given Zymeworks' higher possible upside, equities research analysts plainly believe Zymeworks is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Zymeworks' net margin of -405.31%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Kiniksa Pharmaceuticals International beats Zymeworks on 11 of the 17 factors compared between the two stocks.

Get Zymeworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYME vs. The Competition

Export

Metric	Zymeworks	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.70B	$3.71B	$7.03B	$12.96B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-11.87	9.06	269.91	24.87
Price / Sales	16.04	1,278.42	654.69	108.21
Price / Cash	N/A	44.95	28.89	37.44
Price / Book	6.67	17.97	11.40	6.45
Net Income	-$81.13M	-$13.25M	$3.45B	$347.50M
7 Day Performance	9.82%	5.58%	3.66%	3.77%
1 Month Performance	-7.45%	-1.60%	-0.49%	-0.40%
1 Year Performance	99.26%	61.32%	77.51%	23.55%

Zymeworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYME Zymeworks	2.862 of 5 stars	$23.95 +1.7%	$38.22 +59.6%	+95.8%	$1.70B	$105.96M	N/A	460	Earnings Report Analyst Forecast Analyst Revision
CGON CG Oncology	2.2491 of 5 stars	$71.19 -2.5%	$81.73 +14.8%	+202.2%	$6.44B	$4.04M	N/A	61	Earnings Report Analyst Forecast Analyst Revision
PTCT PTC Therapeutics	4.134 of 5 stars	$68.01 -9.9%	$95.75 +40.8%	+61.5%	$6.26B	$1.73B	N/A	1,410	Gap Down High Trading Volume
XENE Xenon Pharmaceuticals	2.7364 of 5 stars	$62.67 -2.4%	$77.20 +23.2%	+89.5%	$6.20B	$7.50M	N/A	210	Earnings Report Analyst Forecast Analyst Revision
DNTH Dianthus Therapeutics	2.1078 of 5 stars	$106.92 -5.1%	$117.82 +10.2%	+480.6%	$6.16B	$2.04M	N/A	80	Earnings Report Insider Trade Analyst Revision Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYME) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zymeworks (ZYME) Competitors

ZYME vs. CGON, PTCT, XENE, DNTH, and KNSA

How does Zymeworks compare to CG Oncology?

Summary

How does Zymeworks compare to PTC Therapeutics?

Summary

How does Zymeworks compare to Xenon Pharmaceuticals?

Summary

How does Zymeworks compare to Dianthus Therapeutics?

Summary

How does Zymeworks compare to Kiniksa Pharmaceuticals International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zymeworks (ZYME) Competitors

ZYME vs. CGON, PTCT, XENE, DNTH, and KNSA

How does Zymeworks compare to CG Oncology?

Is ZYME or CGON more profitable?

Which has better valuation and earnings, ZYME or CGON?

Which has more risk & volatility, ZYME or CGON?

Do insiders & institutionals believe in ZYME or CGON?

Do analysts prefer ZYME or CGON?

Does the media refer more to ZYME or CGON?

Summary

How does Zymeworks compare to PTC Therapeutics?

Which has more volatility & risk, PTCT or ZYME?

Do insiders and institutionals have more ownership in PTCT or ZYME?

Which has higher earnings and valuation, PTCT or ZYME?

Does the media prefer PTCT or ZYME?

Do analysts rate PTCT or ZYME?

Is PTCT or ZYME more profitable?

Summary

How does Zymeworks compare to Xenon Pharmaceuticals?

Does the media prefer ZYME or XENE?

Which has preferable valuation & earnings, ZYME or XENE?

Do analysts recommend ZYME or XENE?

Is ZYME or XENE more profitable?

Do institutionals and insiders believe in ZYME or XENE?

Which has more volatility & risk, ZYME or XENE?

Summary

How does Zymeworks compare to Dianthus Therapeutics?

Which has more volatility and risk, ZYME or DNTH?

Does the media refer more to ZYME or DNTH?

Do institutionals & insiders hold more shares of ZYME or DNTH?

Do analysts recommend ZYME or DNTH?

Is ZYME or DNTH more profitable?

Which has preferable valuation & earnings, ZYME or DNTH?

Summary

How does Zymeworks compare to Kiniksa Pharmaceuticals International?

Which has preferable earnings and valuation, ZYME or KNSA?

Which has more risk & volatility, ZYME or KNSA?

Do insiders & institutionals have more ownership in ZYME or KNSA?

Does the media refer more to ZYME or KNSA?

Do analysts recommend ZYME or KNSA?

Is ZYME or KNSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYME vs. The Competition

Zymeworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools